Rondy Marc, Larrauri Amparo, Casado Itziar, Alfonsi Valeria, Pitigoi Daniela, Launay Odile, Syrjänen Ritva K, Gefenaite Giedre, Machado Ausenda, Vučina Vesna Višekruna, Horváth Judith Krisztina, Paradowska-Stankiewicz Iwona, Marbus Sierk D, Gherasim Alin, Díaz-González Jorge Alberto, Rizzo Caterina, Ivanciuc Alina E, Galtier Florence, Ikonen Niina, Mickiene Aukse, Gomez Veronica, Kurečić Filipović Sanja, Ferenczi Annamária, Korcinska Monika R, van Gageldonk-Lafeber Rianne, Valenciano Marta
EpiConcept, Paris, France.
National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.
Euro Surveill. 2017 Jul 27;22(30). doi: 10.2807/1560-7917.ES.2017.22.30.30580.
We conducted a multicentre test-negative case-control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42% (95% confidence interval (CI): 22 to 57). It was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus, cancer, lung and heart disease, respectively. Adjusted IVE against influenza B was 52% (95% CI: 24 to 70). It was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: -23 to 67) in patients with diabetes mellitus, lung and heart disease, respectively. 2015/16 IVE estimates against hospitalised influenza in elderly people was moderate against influenza A(H1N1)pdm09 and B, including among those with diabetes mellitus, cancer, lung or heart diseases.
我们在11个欧洲国家的27家医院开展了一项多中心检测阴性病例对照研究，以评估2015/16年度流感疫苗针对≥65岁人群中甲型H1N1pdm09流感和乙型流感住院病例的有效性（IVE）。纳入出现与严重急性呼吸道感染相符症状后7天内进行咽拭子采样的患者。收集了人口统计学、疫苗接种及基础疾病信息。采用逻辑回归分析，我们测量了针对潜在混杂因素进行调整后的IVE。我们纳入了355例甲型H1N1pdm09流感病例、110例乙型流感病例和1274名对照。针对甲型H1N1pdm09流感的调整后IVE为42%（95%置信区间（CI）：22%至57%）。糖尿病、癌症、肺部疾病和心脏病患者的IVE分别为59%（95%CI：23%至78%）、48%（95%CI：5%至71%）、43%（95%CI：8%至65%）和39%（95%CI：7%至60%）。针对乙型流感的调整后IVE为52%（95%CI：24%至70%）。糖尿病、肺部疾病和心脏病患者的IVE分别为62%（95%CI：5%至85%）、60%（95%CI：18%至80%）和36%（95%CI：-23%至67%）。2015/16年度流感疫苗针对老年人住院流感病例的有效性评估显示，针对甲型H1N1pdm09流感和乙型流感的有效性为中等，在患有糖尿病、癌症、肺部或心脏病的人群中亦是如此。
